Table 1.

Analysis of various clinical and biological characteristics at the beginning and during treatment to predict for a sustained CCgR

VariableAll patientsPatients who lost CCgR (n)P
Age (y)1.00
Disease history0.96
    Intolerant to IFN203
    Hematologic resistance to IFN326
    Cytogenetic resistance to IFN458
Time from diagnosis to start of imatinib (mo)1.00
Time to CCgR (mo)0.29
Log reduction at the time of CCgR0.006
    ≥3 log371
    <3 log6018
BCR-ABL/β2 microglobulin ratio % at the time of CCgR0.01